Drug Trial Radar · NCT04803201
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Oct 8, 2021
Primary completion
May 19, 2027
Study completion May 19, 2027
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Conditions
- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Follicular T-Cell Lymphoma
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
CyclophosphamideDrug
Given IV
DoxorubicinDrug
Given IV
VincristineDrug
Given IV
PrednisoneDrug
Given PO
EtoposideDrug
Given IV or PO
DuvelisibDrug
Given PO
Oral azacitidineDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete remission (CR) rateTime frame: Up to 6 months
Locations
96 sites in 1 country. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Active not recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Active not recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
Grady Health System
Atlanta, Georgia · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Completed
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois · Recruiting
AMG Libertyville - Oncology
Libertyville, Illinois · Suspended
Memorial Hospital East
Shiloh, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Recruiting
Iowa Methodist Medical Center
Des Moines, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa · Recruiting
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa · Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana · Recruiting
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan · Recruiting
Essentia Health Cancer Center
Duluth, Minnesota · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Saint Luke's Hospital
Chesterfield, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Mercy Hospital Springfield
Springfield, Missouri · Suspended
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.